Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Clinical Cancer Research

• Publication date

  1999-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 10037184
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties

  1998cited by this paper
• Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol

  1998cited by this paper
• The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer*

  1997cited by this paper
• Taxane Anticancer Agents: Basic Science and Current Status.Gunda I. Georg , Thomas T. Chen , Iwao Ojima , Dolatrai M. Vyas

  1997cited by this paper
• Cancer statistics, 1997

  1997cited by this paper
• Regulation of cellular response to cisplatin-induced DNA damage and DNA repair in cells overexpressing p185erbB-2 is dependent on the ras signaling pathway

  1997cited by this paper
• Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma.

  1997cited by this paper
• The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

  1997cited by this paper
• HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications.

  1997cited by this paper
• Mutant SV40 large T antigen as a therapeutic agent for HER-2/neu-overexpressing ovarian cancer.

  1996cited by this paper
• Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms.

  1996cited by this paper
• Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

  1996cited by this paper
• Cytotoxic effects of gemcitabine-containing regimens against human non-small cell lung cancer cell lines which express different levels of p185neu.

  1996cited by this paper
• Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin.

  1996cited by this paper
• Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells.

  1995cited by this paper
• Prevention of breast tumour development in vivo by downregulation of the p185neureceptor

  1995cited by this paper
• Paclitaxel (taxol)

  1995cited by this paper
• HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model.

  1995cited by this paper
• Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment.

  1995cited by this paper
• HER-2/neu-targeting gene therapy--a review.

  1995cited by this paper
• Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.

  1995cited by this paper
• Drug therapy : paclitaxel (Taxol)

  1995cited by this paper
• Overexpression of c‐erbB‐2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy

  1995cited by this paper
• Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu.

  1995cited by this paper
• Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin.

  1995cited by this paper
• c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.

  1994cited by this paper
• p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.

  1994cited by this paper
• Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.

  1994cited by this paper
• c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties.

  1994cited by this paper
• Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation.

  1994cited by this paper
• Her2 Neu overexpression counteracts the growth effects of C-myc in breast-cancer cells.

  1994cited by this paper
• Mechanisms of deregulated her2/neu expression in breast-cancer cell-lines.

  1994cited by this paper
• Synergism of taxol and gallium nitrate in human breast carcinoma cells: schedule dependency.

  1994cited by this paper
• Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations.

  1993cited by this paper
• Prognostic factors and response to therapy in breast cancer.

  1993cited by this paper
• Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor.

  1992cited by this paper
• HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.

  1992cited by this paper
• Oral cancer progression and c-erbB-2/neu proto-oncogene expression.

  1992cited by this paper
• Emodin, a protein tyrosine kinase inhibitor from Polygonum cuspidatum.

  1992cited by this paper
• Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

  1992cited by this paper
• Breast cancer (Third of three parts)

  1992cited by this paper
• Breast cancer (2).

  1992cited by this paper
• Breast cancer (1)

  1992cited by this paper
• Breast cancer (3).

  1992cited by this paper
• Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells.

  1991cited by this paper
• Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic

  1991cited by this paper
• A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines.

  1991cited by this paper
• Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.

  1991cited by this paper
• Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines.

  1990cited by this paper
• Polymorphic changes of cell phenotype caused by elevated expression of an exogenous NEU proto-oncogene.

  1990cited by this paper
• Low metastatic potential of clone from murine colon adenocarcinoma 26 increased by transfection of activated c-erbB-2 gene.

  1990cited by this paper
• Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung.

  1990cited by this paper
• Amplification and expression of the c‐erb B‐2/neu proto‐oncogene in human bladder cancer

  1990cited by this paper
• Amplification of the proto-neu oncogene facilitates oncogenic activation by a single point mutation.

  1989cited by this paper
• Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts.

  1989cited by this paper
• Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases.

  1989cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• Amplification and rearrangement of c-erb B proto-oncogenes in cancer of human female genital tract.

  1989cited by this paper
• Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.

  1988cited by this paper
• Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo.

  1988cited by this paper
• Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue.

  1988cited by this paper
• erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.

  1987cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells.

  1987cited by this paper
• Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185.

  1986cited by this paper
• Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen.

  1986cited by this paper
• Molecular cloning of the neu gene: absence of gross structural alteration in oncogenic alleles.

  1986cited by this paper
• Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies.

  1985cited by this paper
• Monoclonal antibody to a membrane glycoprotein inhibits the acrosome reaction and associated Ca2+ and H+ fluxes of sea urchin sperm.

  1985cited by this paper
• Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

  1983cited by this paper
• Enzyme and metabolic inhibitors

  1963cited by this paper

• Reawakening Differentiation Therapy in Acute Myeloid Leukemia: A Comprehensive Review of ATRA-Based Combination Strategies

  2026cites this paper
• Emodin Decreases Tumor-Associated Macrophages Accumulation and Suppresses Bladder Cancer Development by Inhibiting CXCL1 Secretion from Cancer-Associated Fibroblasts

  2025cites this paper
• Unraveling the mechanism of the anticancer potential of emodin using 2D and spheroid models of A549 cells.

  2024cites this paper
• Progress on the mechanism of action of emodin against breast cancer cells

  2024cites this paper
• Therapeutic Potential of 1,8-Dihydroanthraquinone Derivatives for Breast Cancer

  2023cites this paper
• Emodin coupled with high LET neutron beam—a novel approach to treat on glioblastoma

  2022cites this paper
• The versatile emodin: A natural easily acquired anthraquinone possesses promising anticancer properties against a variety of cancers

  2022cites this paper
• In Vitro Anticancer Screening and Preliminary Mechanistic Study of A-Ring Substituted Anthraquinone Derivatives

  2022cites this paper
• Phytochemical Targeting of Mitochondria for Breast Cancer Chemoprevention, Therapy, and Sensitization

  2022cites this paper
• Advances in Understanding the Role of Aloe Emodin and Targeted Drug Delivery Systems in Cancer

  2022cites this paper
• Identification of Potential Therapeutic Genes and Pathways in Phytoestrogen Emodin Treated Breast Cancer Cell Lines via Network Biology Approaches

  2021cites this paper
• Journey of anthraquinones as anticancer agents – a systematic review of recent literature

  2021cites this paper
• Emodin - A natural anthraquinone derivative with diverse pharmacological activities.

  2021cites this paper
• A metabolite that exhibits anti-neoplastic activities by modulating multiple oncogenic targets.

  2021cites this paper
• A Network Pharmacology Analysis of the Systems-Perspective Anticancer Mechanisms of the Herbal Drug FDY2004 for Breast Cancer

  2021cites this paper
• [89Zr]-Pertuzumab PET Imaging Reveals Paclitaxel Treatment Efficacy Is Positively Correlated with HER2 Expression in Human Breast Cancer Xenograft Mouse Models

  2021cites this paper
• Is Emodin with Anticancer Effects Completely Innocent? Two Sides of the Coin

  2021cites this paper
• Anthraquinone: a promising scaffold for the discovery and development of therapeutic agents in cancer therapy.

  2020cites this paper
• The potential role of dietary plant ingredients against mammary cancer: a comprehensive review

  2020cites this paper
• Aloe-emodin as drug candidate for cancer therapy

  2018cites this paper
• Determination of Phytoestrogenic Potential of Anthranoids by Molecular Docking Studies

  2018cites this paper
• Anti-leukemic activity of a four-plant mixture in a leukemic rat model

  2018cites this paper
• HER2 positivity may confer resistance to therapy with paclitaxel in breast cancer cell lines

  2018cites this paper
• Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism

  2018cites this paper
• Emodin inhibits the proliferation and invasion of bladder cancer cells via down-regulating Notch1.

  2017cites this paper
• Molecular Docking of Anthranoids on Some Targeted Human Proteins

  2017cites this paper
• The nuclear factor-kappa B pathway and response to treatment in breast cancer.

  2017cites this paper
• Fallopia japonica: Bioactive Secondary Metabolites and Molecular Mode of Anticancer Traditional Medicine & Clinical Naturopathy

  2016cites this paper
• Caracterización de fármacos (emodina, ketorolaco, indometacina y piroxicam) sobre nanopartículas metálicas mediante espectroscopía molecular (sers y mef)

  2016cites this paper
• Convection-enhanced delivery of sorafenib and suppression of tumor progression in a murine model of brain melanoma through the inhibition of signal transducer and activator of transcription 3.

  2016cites this paper
• Aloe-emodin inhibits HER-2 expression through the downregulation of Y-box binding protein-1 in HER-2-overexpressing human breast cancer cells

  2016cites this paper
• South Asian Medicinal Compounds as Modulators of Resistance to Chemotherapy and Radiotherapy

  2016cites this paper
• Em08red, a dual functional antiproliferative emodin analogue, is a downregulator of ErbB2 expression and inducer of intracellular oxidative stress

  2015cites this paper
• A novel combined micellar system of lapatinib and Paclitaxel with enhanced antineoplastic effect against human epidermal growth factor receptor-2 positive breast tumor in vitro.

  2015cites this paper
• A NOVEL μ-FLUIDIC CHANNEL ASSISTED ENCAPSULATION TECHNIQUE FOR LAYER-BY-LAYER POLYMER NANO- AND MICROCARRIER FABRICATION A Thesis Presented to The Graduate Faculty of The University of Akron In Partial Fulfillment of the Requirements for the Degree Master of Science

  2015cites this paper
• Cytotoxic Potential and Molecular Characterization of Fungal Endophytes from Selected High Value Medicinal Plants of the Kashmir Valley – India

  2015cites this paper
• Exometabolom analysis of breast cancer cell lines: Metabolic signature

  2015cites this paper
• +TIP EB1 downregulates paclitaxel‑induced proliferation inhibition and apoptosis in breast cancer cells through inhibition of paclitaxel binding on microtubules.

  2015cites this paper
• Emodin azide methyl anthraquinone derivative induced G0/ G1 arrest in HER2/neu-overexpressing MDA-MB-453 breast cancer cells.

  2014cites this paper
• Isotonic sodium bicarbonate-triggered emodin release from borate stabilized emodin nanoparticles-loaded polymeric microgel films.

  2014cites this paper
• Emodin enhances ATRA-induced differentiation and induces apoptosis in acute myeloid leukemia cells.

  2014cites this paper
• A Fast and Simple HPLC–UV Method for Simultaneous Determination of Emodin and Quinalizarin from Fermentation Broth of Aspergillus. ochraceus lp_0429

  2014cites this paper
• Dominance of most tolerant species in multi-type lattice Widom–Rowlinson models

  2014cites this paper
• Relationship Between Reactive Oxygen Species and Emodin Production in Aspergillus ochraceus

  2014cites this paper
• Emodin (1, 3, 8-trihydroxy-6-methylanthraquinone), a natural anthraquinone derivative inhibits growth and induces apoptosis in human liver cancer cells through reactive oxygen species generation

  2014cites this paper
• The Influence of Short Chain Fatty Acids on Biosynthesis of Emodin by Aspergillus ochraceus LP-316

  2014cites this paper
• Natural or Synthetic Therapeutics That Block PAKs

  2013cites this paper
• Apoptosis and DNA intercalating activities of novel emodin derivatives

  2013cites this paper
• Therapeutic effects of autologous lymphocytes activated with trastuzumab for xenograft mouse models of human breast cancer.

  2013cites this paper
• Medicinal Plants of Central Asia: Uzbekistan and Kyrgyzstan

  2013cites this paper
• Phytochemicals As Chemosensitizers: From Molecular Mechanism to Clinical Significance

  2013influential citation
• Characterization of Apoptosis Induced by Emodin and Related Regulatory Mechanisms in Human Neuroblastoma Cells

  2013cites this paper
• Targeted abrogation of diverse signal transduction cascades by emodin for the treatment of inflammatory disorders and cancer.

  2013cites this paper
• Preparation of novel antiproliferative emodin derivatives and studies on their cell cycle arrest, caspase dependent apoptosis and DNA binding interaction.

  2013cites this paper
• Synergistic effects of curcumin with emodin against the proliferation and invasion of breast cancer cells through upregulation of miR-34a

  2013cites this paper
• Emodin induces embryonic toxicity in mouse blastocysts through apoptosis.

  2012cites this paper
• Cell-type dependent response of melanoma cells to aloe emodin.

  2012cites this paper
• Taxane resistance in breast cancer: a closed HER2 circuit?

  2012cites this paper
• Emodin affects ERCC1 expression in breast cancer cells

  2012cites this paper
• Injurious Effects of Emodin on Maturation of Mouse Oocytes, Fertilization and Fetal Development via Apoptosis

  2012cites this paper
• An Overview of the Current Development of Phytoremedies for Breast Cancer

  2012cites this paper
• Avaliação da expressão dos genes envolvidos na via de sinalização induzida pela proteína dermicidina no câncer de mama.

  2012cites this paper
• Blockade of Her2/neu binding to Hsp90 by emodin azide methyl anthraquinone derivative induces proteasomal degradation of Her2/neu.

  2011cites this paper
• Enhanced effect of gemcitabine by emodin against pancreatic cancer in vivo via cytochrome C-regulated apoptosis.

  2011cites this paper
• Emodin Induces Apoptotic Death in Murine Myelomonocytic Leukemia WEHI-3 Cells In Vitro and Enhances Phagocytosis in Leukemia Mice In Vivo

  2011cites this paper
• Repair and Reconstruction of a Resected Tumor Defect Using a Composite of Tissue Flap–Nanotherapeutic–Silk Fibroin and Chitosan Scaffold

  2011cites this paper
• Role of Delta16HER2 splice variant in breast tumor progression and response to HER2-Targeted therapy.

  2011cites this paper
• AVALIAÇÃO DA EXPRESSÃO DOS GENES ENVOLVIDOS NA VIA DE SINALIZAÇÃO INDUZIDA PELA PROTEÍNA DERMICIDINA NO CÂNCER DE MAMA

  2011cites this paper
• Wilms’ tumor 1 silencing decreases the viability and chemoresistance of glioblastoma cells in vitro: a potential role for IGF-1R de-repression

  2011cites this paper
• Modulation of Rad51, ERCC1, and thymidine phosphorylase by emodin result in synergistic cytotoxic effect in combination with capecitabine.

  2011cites this paper
• Separation, purification and structural analysis of emodin and quinalizarin from Aspergillus .ochraceus

  2011cites this paper
• Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy.

  2010cites this paper
• Role of Rad 51 Down-Regulation and Extracellular Signal-Regulated Kinases 1 and 2 Inactivation in Emodin and Mitomycin C-Induced Synergistic Cytotoxicity in Human Non – Small-Cell Lung Cancer Cells

  2010influential citation
• Evaluation of HER2/neu oncoprotein in serum and tissue samples of women with breast cancer: correlation with clinicopathological parameters.

  2010cites this paper
• Suppression of ERCC1 and Rad51 expression through ERK1/2 inactivation is essential in emodin-mediated cytotoxicity in human non-small cell lung cancer cells.

  2010cites this paper
• The Role of Oncogene Activation in Tumor Progression

  2010cites this paper
• Role of Rad51 Down-Regulation and Extracellular Signal-Regulated Kinases 1 and 2 Inactivation in Emodin and Mitomycin C-Induced Synergistic Cytotoxicity in Human Non–Small-Cell Lung Cancer Cells

  2010influential citation
• Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2.

  2010cites this paper
• Silk fibroin-derived nanoparticles for biomedical applications.

  2010cites this paper
• The anthraquinone derivative emodin attenuates methamphetamine-induced hyperlocomotion and startle response in rats.

  2010cites this paper
• Rhein lysinate suppresses the growth of tumor cells and increases the anti-tumor activity of Taxol in mice.

  2009cites this paper
• Emodin induces a reactive oxygen species-dependent and ATM-p53-Bax mediated cytotoxicity in lung cancer cells.

  2009cites this paper
• Role of Rad51 downregulation and ERK1/2 inactivation in emodin and mitomycin C-induced synergistic cytotoxicity in human non-small cell lung cancer cells

  2009influential citation
• Rhein lysinate suppresses the growth of breast cancer cells and potentiates the inhibitory effect of Taxol in athymic mice

  2009cites this paper
• Emodin has cytotoxic and protective effects in Rat C6 glioma cells: Roles of Mdr1a and NF-kappa B in cell survival

  2009cites this paper
• Suppression of ErbB-2 in androgen-independent human prostate cancer cells enhances cytotoxic effect by gemcitabine in an androgen-reduced environment.

  2009cites this paper
• Emodin targets the β-hydroxyacyl-acyl carrier protein dehydratase from Helicobacter pylori: enzymatic inhibition assay with crystal structural and thermodynamic characterization

  2009cites this paper
• Emodin Has Cytotoxic and Protective Effects in Rat C6 Glioma Cells: Roles of Mdr1a and Nuclear Factor κB in Cell Survival

  2009cites this paper
• Effects of emodin on the gene expression profiling of human breast carcinoma cells.

  2009cites this paper
• Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivation.

  2009cites this paper
• Emodin sensitizes paclitaxel-resistant human ovarian cancer cells to paclitaxel-induced apoptosis in vitro.

  2009cites this paper
• Methanolic extract of Teucrium polium L. potentiates the cytotoxic and apoptotic effects of anticancer drugs of vincristine, vinblastine and doxorubicin against a panel of cancerous cell lines.

  2008cites this paper
• Natural Agents That Can Sensitize Tumor Cells to Chemotherapy and Radiation Therapy

  2008cites this paper
• Feasibility evaluation of emodin (rhubarb extract) as an inhibitor of pancreatic cancer cell proliferation in vitro.

  2008cites this paper
• Emodin azide methyl anthraquinone derivative triggers mitochondrial-dependent cell apoptosis involving in caspase-8-mediated Bid cleavage

  2008cites this paper
• Antitumor and antimetastatic actions of anthrone‐C‐glucoside, cassialoin isolated from Cassia garrettiana heartwood in colon 26‐bearing mice

  2008cites this paper
• HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer.

  2008cites this paper
• Prospect for Anti-Her 2 Receptor Therapy in Breast Cancer

  2008cites this paper
• The anthraquinone derivative Emodin ameliorates neurobehavioral deficits of a rodent model for schizophrenia

  2008cites this paper
• Chemosensitization by emodin, a plant-derived anti-cancer agent: mechanism of action

  2008cites this paper